^
    1d
    A real-world study of toripalimab in the treatment of advanced solid tumor patients in China (ChiCTR2600121488)
    P4, N=300, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial • Real-world evidence
    |
    Loqtorzi (toripalimab-tpzi)
    1d
    A single-arm, open-label, single-center phase II clinical study to evaluate the efficacy and safety of vebecototota monoclonal antibody combined with putrilimab as first-line treatment for patients with recurrent/metastatic nasopharyngeal carcinoma (ChiCTR2600121458)
    P2, N=37, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P2 trial
    1d
    A Single-Center, Exploratory Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma (ChiCTR2600120749)
    P=N/A, N=68, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    1d
    A multicenter retrospective study on the detection of EBV-related antibody markers by chemiluminescence to assist in the early diagnosis of nasopharyngeal carcinoma (ChiCTR2600120294)
    P=N/A, N=0, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    1d
    The Role of Pedicled Vascularized Flaps in Reconstruction After Endoscopic Skull Base Surgery (ChiCTR2600120134)
    P=N/A, N=300, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
    New trial
    1d
    Efficacy and Safety of Sequential Multimodal Dose-Fractionated Radiotherapy Following Immunochemotherapy for Recurrent and Metastatic Nasopharyngeal Carcinoma:A Prospective, Single-Arm, Phase II Exploratory Study (ChiCTR2600120118)
    P2, N=24, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P2 trial
    2d
    Identification of Nutritional Status Trajectories in Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy Based on the LCGM Model (ChiCTR2600119921)
    P=N/A, N=1000, The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University
    New trial
    2d
    Benmelstobart Plus TPF Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 2 Trial (ChiCTR2600119884)
    P2, N=36, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • docetaxel • 5-fluorouracil • Andewei (benmelstobart)
    2d
    The efficacy of 2 cycles versus 3 cycles of induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma (ChiCTR2600119540)
    P=N/A, N=500, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial
    2d
    Randomized Controlled Trial of Camrelizumab Combined with EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (ChiCTR2600119577)
    P4, N=246, Shanghai Ninth People's Hospital， Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital， Shanghai JiaoTong University
    New P4 trial
    |
    Erbitux (cetuximab) • AiRuiKa (camrelizumab)
    2d
    A Retrospective Observational Study on the Real-World Treatment Patterns and Survival Outcomes of Elderly Patients with Nasopharyngeal Carcinoma (ChiCTR2600119331)
    P=N/A, N=100, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial • HEOR • Real-world evidence
    2d
    A Phase II Clinical Study of Induction Therapy with EGFR Monoclonal Antibody (Nimotuzumab) Combined with Gemcitabine and S-1 for Locally Advanced Nasopharyngeal Carcinoma in Patients Intolerant to Cisplatin (ChiCTR2600118783)
    P2, N=28, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New P2 trial
    |
    cisplatin • gemcitabine • Teysuno (gimeracil/oteracil/tegafur) • TheraCIM (nimotuzumab)